Browsing Tag
Eli Lilly and Company
145 posts
Lilly (NYSE: LLY) to acquire Orna Therapeutics for $2.4bn to expand in vivo CAR-T strategy
Eli Lilly and Company (LLY) to acquire Orna Therapeutics for up to $2.4B. Explore how in vivo CAR-T and circular RNA may transform autoimmune therapy.
Lilly selects Lehigh Valley, Pennsylvania for obesity drug manufacturing plant
Lilly is building a $3.5B injectable medicine facility in Pennsylvania to scale retatrutide. Find out how this reshapes the obesity drug market and U.S. supply.
Eli Lilly blocked in European heart failure label push: Is the GLP‑1 race now tilting to Novo Nordisk?
Find out why Eli Lilly’s bid to expand Mounjaro’s EU label for heart failure was declined and what it means for the company’s growth strategy and competitive standing.
Can weight loss drugs cause fatal pancreas illness? UK raises red flag on GLP-1 therapies
UK strengthens pancreatitis risk warning for GLP-1 weight loss and diabetes drugs like Wegovy and Mounjaro. Find out what it means for health systems and pharma.
Eli Lilly’s sofetabart mipitecan earns FDA Breakthrough Therapy status in platinum-resistant ovarian cancer
Eli Lilly's sofetabart mipitecan receives FDA Breakthrough Therapy designation in platinum-resistant ovarian cancer. Find out what this means for the ADC space.
Lilly to acquire Ventyx Biosciences (Nasdaq: VTYX) in a high-conviction bet on oral inflammation therapies
Eli Lilly is acquiring Ventyx Biosciences for $1.2B to advance oral inflammation therapies. Find out what this means for biotech M&A and chronic care strategy.
Lilly’s oral GLP-1 orforglipron sustains weight loss after injectables in pivotal Phase 3 trial
Lilly’s orforglipron helped patients maintain weight loss after injectable GLP-1s in a Phase 3 trial. Find out how this could reshape obesity treatment paths.
Eli Lilly’s Inluriyo and Verzenio combo data reshape outlook for ER+, HER2– metastatic breast cancer treatment
Eli Lilly’s EMBER-3 update boosts Inluriyo’s profile in breast cancer care—find out how its all-oral combo with Verzenio could shift treatment standards.
Mazdutide phase 1b results from Innovent Biologics offer new hope for adolescent obesity in China
Find out how Innovent Biologics’ mazdutide trial could change adolescent obesity treatment in China—phase 3 launch is next.
Can Novo Nordisk catch up—or will Lilly run away with the metabolic crown?
Explore how Eli Lilly and Company and Novo Nordisk are battling for dominance in the metabolic health market, and what could decide the next phase of the obesity drug race.